title: Intravitreal combination of triamcinolone acetonide and bevacizumab (Kenacort-Avastin) in diffuse diabetic macular edema.
abstract: OBJECTIVE
  To evaluate the effect of intravitreal injection of the combination of Triamcinolone Acetonide and Bevacizumab in patients with diabetic macular edema.
  
  
  METHODS
  Twenty seven eyes of 17 patients with diabetic macular edema were treated with an intravitreal injection of triamcinolone acetonide (2 mg) combined with bevacizumab (1.25 mg).
  
  
  RESULTS
  During the 6 months follow-up period 24 eyes (89%) had to repeat the treatment according to the monthly follow-up examination.The mean visual acuity and the central macular thickness improved significantly (P<0.05) throughout the follow-up period.
  
  
  CONCLUSIONS
  Intravitreal combination of Triamcinolone Acetonide and Bevacizumab seems to be effective in improving visual acuity and macular edema in patients with diabetic maculopathy.
authors: Retina Service, University Eye Clinic of Heraklion, Crete, Greece. tsilimb@med.uoc.gr
authors: Miltiadis K
authors: MK
authors: Tsilimbaris
authors: Vassilios
authors: V
authors: Pandeleondidis
authors: Theoni
authors: T
authors: Panagiototglou
authors: Vassiliki
authors: V
authors: Arvanitaki
authors: Sofia
authors: S
authors: Fragiskou
authors: Maria
authors: M
authors: Eleftheriadou
authors: Chrysanthi
authors: C
authors: Tsika
authors: Theokliti
authors: T
authors: Papadaki
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000473:pathology; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D056965:Injections, Intraocular; D008266:Macula Lutea / Q000187:drug effects / Q000473:pathology; D008269:Macular Edema / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004338:Drug Combinations; D007166:Immunosuppressive Agents; D000068258:Bevacizumab; D014222:Triamcinolone Acetonide